| Nov 20 |
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Nov 18 |
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
|
| Nov 18 |
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
|
| Nov 18 |
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
|
| Nov 15 |
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
|
| Nov 4 |
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 4 |
Adverum Biotechnologies GAAP EPS of -$1.30 beats by $0.01
|
| Nov 4 |
Adverum Biotechnologies: Q3 Earnings Snapshot
|
| Nov 4 |
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
|
| Oct 16 |
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
|
